Intramucosal variant of nasal natural killer (NK)/T cell lymphoma has a better survival than does invasive variant: Implication on loss of E26 transformation-specific sequence 1 (ETS-1) and T-box expressed in T cells (T-bet) with invasion

Histopathology

Volumn 60, Issue 2, 2012, Pages 287-295

  Lin, Ting Chu ^a   Chen, Shee Uan ^a   Chen, Ya Fang ^a   Chang, Yeun Chung ^a   Lin, Chung Wu ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

E26 transformation specific sequence 1; Intramucosal; Nasal NK T cell lymphoma; T bet

Indexed keywords

CD56 ANTIGEN; GRANZYME B; STAT1 PROTEIN; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 1;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASAL NATURAL KILLER T CELL LYMPHOMA; NATURAL KILLER CELL; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; ANTIGENS, CD56; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NOSE NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEIN C-ETS-1; SEX CHARACTERISTICS; STAT1 TRANSCRIPTION FACTOR; SURVIVAL RATE; T-BOX DOMAIN PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84255204441     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04086.x     Document Type: Article

References (40)

1. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19; 2186-2194.
2. Liang X, Graham DK. Natural killer cell neoplasms. Cancer 2008; 112; 1425-1436.
3. Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106; 3785-3790.
4. Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol. 2006; 24; 612-618.
5. Swerdlow SH, Campo E, Harris NL et al. Tumours of haematopoietic and lymphoid tissues, WHO classification of tumours. Lyon: IARC Press, 2008.
6. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006; 20; 123-137.
7. Lieto LD, Borrego F, You CH et al. Human CD94 gene expression: dual promoters differing in responsiveness to IL-2 or IL-15. J. Immunol. 2003; 171; 5277-5286.
8. Shnyreva M, Weaver WM, Blanchette M et al. Evolutionarily conserved sequence elements that positively regulate IFN-gamma expression in T cells. Proc. Natl Acad. Sci. U S A 2004; 101; 12622-12627.
9. Djuretic IM, Levanon D, Negreanu V et al. Transcription factors T-bet and Runx3 cooperate to activate IFNg and silence IL4 in T helper type 1 cells. Nat. Immunol. 2007; 2; 145-153.
10. Afkarian M, Sedy JR, Yang J et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat. Immunol. 2002; 3; 549-557.
11. Yang Y, Ochando JC, Bromberg JS et al. Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNγ/Stat1 signals. Blood 2007; 110; 2494-2500.
12. Reeves RK, Gillis J, Wong FE et al. CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection. Blood 2010; 115; 4439-4446.
13. Lin CW, Chen YH, Chuang YC et al. CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Blood 2003; 102; 2623-2631.
14. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5; 649-655.
15. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31; 1860-1861.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 2000; 92; 205-216.
17. Cong P, Raffeld M, Teruya-Feldstein J et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 2002; 99; 3376-3382.
18. Staudt LM. A closer look at follicular lymphoma. N. Engl. J. Med. 2007; 356; 741-742.
19. Azab MB, Henry-Amar M, Rougier P et al. Prognostic factors in primary gastrointestinal non-Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer 1989; 64; 1208-1217.
20. El-Zahabi LM, Jamali FR, El-Hajj II et al. The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication. Gastrointest. Endosc. 2007; 65; 89-96.
21. Mehra M, Agarwal B. Endoscopic diagnosis and staging of mucosa-associated lymphoid tissue lymphoma. Curr. Opin. Gastroenterol. 2008; 24; 623-626.
22. Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphoma of the intestine. Am. J. Pathol. 1992; 141; 1361-1371.
23. van de Water JM, Cillessen SA, Visser OJ et al. Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract. Res. Clin. Gastroenterol. 2010; 24; 43-56.
24. Spencer J, Cerf-Bensussan N, Jarry A et al. Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes. Am. J. Pathol. 1988; 132; 1-5.
25. Verbeek WH, Goerres MS, von Blomberg BM et al. Flow cytometric determination of aberrant intraepithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin. Immunol. 2008; 126; 48-56.
26. Chinen H, Matsuoka K, Sato T et al. Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007; 133; 559-573.
27. Freud AG, Yokohama A, Becknell B et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med. 2006; 203; 1033-1043.
28. Dittmer J. The biology of the Ets1 proto-oncogene. Mol. Cancer 2003; 2; 29.
29. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003; 303; 11-34.
30. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 2005; 41; 2462-2478.
31. Barton K, Muthusamy N, Fischer C et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 1998; 9; 555-563.
32. Walunas TL, Wang B, Wang CR et al. Cutting edge: the Ets1 transcription factor is required for the development of NK T cells in mice. J. Immunol. 2000; 164; 2857-2860.
33. Wilson V, Conlon FL. The T-box family. Genome Biol. 2002; 3; 3008.1-3008.7.
34. Naiche LA, Harrelson Z, Kelly RG et al. T-box genes in vertebrate development. Annu. Rev. Genet. 2005; 39; 219-239.
35. Szabo SJ, Kim ST, Costa GL et al. A novel transcription factor, T-bet, diValpha14i NKT cells. Cell 2000; 100; 659-669.
36. Townsend MJ, Weinmann AS, Matsuda JL et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004; 20; 477-494.
37. Grenningloh R, Kang BY, Ho IC. Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses. J. Exp. Med. 2005; 201; 615-626.
38. Takeuchi K, Yokoyama M, Ishizawa S et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 2010; 116; 5631-5637.
39. Mansoor A, Pittaluga S, Beck PL et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathological features and follow-up in a unique case series. Blood 2010; 117; 1447-1452.
40. Lin CW, Lee WS, Chang CL, Yang JY, Hsu SM. Restricted KIR repertoire without TCR rearrangement defines a true NK cell lineage in a subset of sinonasal lymphoma. Am. J. Pathol. 2001; 159; 1671-1679.